AbbVie Asks Justices To Hear Sham Litigation Exception Case
Unless AbbVie was using its patent litigation over its testosterone treatment Androgel as an anticompetitive weapon, the Third Circuit was wrong to declare its lawsuits a sham and the U.S. Supreme...To view the full article, register now.
Already a subscriber? Click here to view full article